Unum Therapeutics Inc.
Battling cancer with mix-and-match immune-system components
This article was originally published in Start Up
Unum Therapeutics Inc. is developing a new way of treating cancer that combines components of two different immune-system cells, natural killer cells and T cells. The start-up's therapeutic approach calls for modifying patients' own T cells with a hybrid molecule, called an antibody-coupled T-cell receptor , then co-administering them with antibodies designed to recognize specific proteins on the surface of tumors.
You may also be interested in...
Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.
Eventually, someone is going to have clinical and commercial success with a personalized cancer therapy. Learning from the mistakes of Dendreon and others, Argos Therapeutics expects to be first, and automation is its key.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.